Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion
Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion and blood pool agent. Preclinical studies indicate that the proprietary agent, called PH-50, has potential in coronary, cardiac, great vessel, and renal arterial CT. Through luminaries at Stanford University, the New Hope, PA, company also hopes to explore the use of this agent as a means for imaging soft noncalcified plaques in coronary arteries, where its presence is a marker of likelihood to rupture and cause sudden death.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.